CYP2C9 rs115232898: What Your Genotype Means
The rs115232898 variant is a genetic change located within the CYP2C9 gene. It is primarily studied for its potential to reduce the activity of the CYP2C9 enzyme, which may influence how the body processes certain medications.
What each genotype means
Normal enzyme function
This genotype represents the most common form of the DPYD gene, which is responsible for producing an enzyme that helps break down certain anticancer medications. Individuals with this profile are generally expected to have standard enzyme activity. Please discuss any prescribed medication dosing with your clinician or pharmacist.
This is the most common genotype found across all global populations.
Reduced enzyme activity
This genotype is associated with reduced activity of the DPYD enzyme, which may affect how your body processes specific fluoropyrimidine anticancer drugs. Research indicates this variant is more frequently observed in individuals of African ancestry and has been linked to potential drug-related toxicity in some clinical reports. Please consult your healthcare provider or pharmacist to discuss how this may influence your specific treatment plan.
Carried by approximately 3–5% of individuals with African ancestry, making it a relatively common variant in that population.
Significantly reduced enzyme activity
This genotype indicates the presence of two copies of the variant, which may lead to a more pronounced reduction in DPYD enzyme activity compared to carrying a single copy. Because this enzyme is critical for metabolizing certain chemotherapy agents, this profile may increase the risk of adverse drug reactions. It is essential to discuss this genetic finding with your oncologist or pharmacist before starting any relevant medication.
This genotype is rare, occurring at a very low frequency even in populations where the variant is more commonly observed.
Understanding the Variant and Gene
The rs115232898 variant is a single-nucleotide polymorphism (SNP) found in the CYP2C9 gene. This gene provides instructions for making an enzyme that plays a critical role in the metabolism of many common drugs, including anticoagulants and nonsteroidal anti-inflammatory drugs. The CYP2C9 enzyme is responsible for breaking down these substances so they can be cleared from the body. When a variant like rs115232898 is present, it can alter the structure or function of this enzyme. Research indicates that this specific variant is associated with decreased enzymatic activity, which may lead to slower drug metabolism. Because the CYP2C9 enzyme is essential for processing a wide range of therapeutic agents, variations in its genetic code are a major focus of pharmacogenomics, the study of how genes affect an individual's response to medications.
Research and Clinical Associations
Scientific research has identified rs115232898 as a variant of interest, particularly in the context of pharmacogenomics. Studies have shown that this variant can lead to reduced function of the CYP2C9 enzyme. In clinical settings, reduced enzyme activity can mean that drugs metabolized by CYP2C9 remain in the bloodstream for longer periods, potentially increasing the risk of side effects or requiring dosage adjustments. While the evidence for its impact is considered moderate, it is frequently investigated alongside other known variants to better understand drug safety and efficacy. It is important to note that the clinical significance of this variant can vary depending on the specific medication being used and the individual's overall genetic profile. Researchers continue to study how this variant interacts with other genetic factors to influence patient outcomes in diverse populations.
Population Frequency and Considerations
The rs115232898 variant is generally considered rare, though its frequency can differ significantly across various ancestral groups. Research has highlighted that this variant is more commonly observed in individuals of African ancestry compared to other global populations. Because pharmacogenomic guidelines are often based on data from specific ancestral groups, the presence of this variant in underrepresented populations is a critical area of ongoing study. Understanding the distribution of such variants is essential for developing inclusive and accurate precision medicine strategies. If you are concerned about how your genetic makeup might affect your response to a specific medication, it is essential to discuss this with your healthcare provider or a clinical pharmacist. They can provide guidance based on your medical history and current clinical guidelines, ensuring that any decisions regarding your treatment are safe and personalized.
How common is this variant?
The rs115232898 variant is rare globally but is more frequently observed in populations of African ancestry, where it has been identified in approximately 1-4% of individuals.
Frequently asked questions
What is the CYP2C9 gene?
The CYP2C9 gene provides instructions for making an enzyme that helps the body break down and eliminate many different medications, including blood thinners and pain relievers.
Does having this variant mean I will have a bad reaction to medication?
Not necessarily. While this variant can affect how your body processes certain drugs, many factors influence your response to medication. Always consult your doctor before making changes to your prescriptions.
Should I get tested for this variant?
Genetic testing for pharmacogenomics is typically recommended by healthcare providers in specific clinical situations, such as when starting a medication with a narrow therapeutic index. Discuss the necessity of testing with your clinician.
Where can I find more information on pharmacogenomics?
The Pharmacogenomics Knowledgebase (PharmGKB) and MedlinePlus Genetics are excellent, reliable resources for learning about how genetic variations influence drug response.
Sources & further reading
Educational information only, last refreshed 11/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs115232898?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C9
A variant profiled in Nigerian cohorts to assess its role in the metabolism of anticancer drugs.
Rare variant in the CYP2C9 gene potentially impacting enzyme activity and drug metabolism; clinical significance requires further validation.
Missense mutation defining the CYP2C9*5 allele that dramatically lowers metabolic activity towards oral anticoagulants and anti-epileptic medications.
Coding variant conferring the CYP2C9*3 allele (often mislabeled as *4 in older literature) with decreased enzymatic activity affecting clearance of drugs such as warfarin and phenytoin.
A rare variant in the CYP2C9 gene that may impact the metabolism of various clinical drugs.
The CYP2C9*2 variant (p.Arg144Cys) results in reduced enzymatic activity, significantly impacting the metabolism and required dosing of substrates such as warfarin and irbesartan.